SUPPORT for Patients and Communities Reauthorization Act of 2025
- Bill Number
- S. 2121
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-18: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-06-23T15:11:03Z
AI-Generated Summary
Summary of S. 2121: SUPPORT for Patients and Communities Reauthorization Act of 2025
Purpose
This legislation reauthorizes and expands federal programs under the Public Health Service Act and other laws to address the opioid crisis and related substance use disorders (SUD). It focuses on preventing misuse, improving treatment access, supporting recovery, and enhancing related public health efforts, including education, training, and coordination. The act aims to sustain and strengthen initiatives from the original 2018 SUPPORT Act through fiscal years 2026–2030.
Key Provisions
The bill is organized into four titles, reauthorizing grants, programs, and activities with updated funding and requirements.
Title I: Prevention
- Funds prenatal and postnatal health programs to support mothers and infants affected by substance exposure ($4.25 million annually).
- Expands monitoring and education on infections linked to illicit drug use.
- Enhances overdose prevention grants, including innovative detection methods like wastewater surveillance (while respecting privacy laws) and support for test strips detecting substances like fentanyl and xylazine ($505.579 million annually).
- Establishes a comprehensive fetal alcohol spectrum disorders (FASD) program, including education, research, capacity building, and grants to states, tribes, and nonprofits ($12.5 million annually); requires annual reports on FASD activities.
- Promotes flexibility in Prescription Drug Monitoring Program (PDMP) systems by prohibiting federal mandates on specific vendors.
- Increases funding for first responder training on overdose reversal drugs ($57 million annually) and the National Child Traumatic Stress Initiative ($98.887–$100 million annually).
- Protects the 988 Suicide Prevention Lifeline from cybersecurity threats, mandates reporting of vulnerabilities, and requires a Government Accountability Office study on risks.
- Boosts trauma monitoring and reporting ($9 million annually) and creates a federal work group on fentanyl contamination in illicit drugs to improve awareness and responses.
- Issues guidance on at-home drug disposal systems and requires an FDA report assessing opioid drugs' public health impacts, including nonaddictive alternatives.
Title II: Treatment
- Reauthorizes residential treatment for pregnant and postpartum women with SUD ($38.931 million annually) and expands access to addiction medicine providers.
- Extends mental and behavioral health training grants through 2030 and increases loan repayment for SUD treatment workforce ($40 million annually).
- Removes expiration on model training programs for handling SUD patient records.
- Establishes a task force on trauma-informed care (extending to 2030) and simplifies grants for enhancing SUD treatment access.
- Reviews state use of mental health block grants for early psychosis care and updates guidance on evidence-based services.
- Directs review of scheduling for buprenorphine-naloxone combination products to potentially ease access for treatment.
Title III: Recovery
- Increases funding for recovery community services ($17 million annually) and peer support technical assistance, including a new regional center (with evaluation by 2029).
- Updates comprehensive opioid recovery centers to include referral-based services and additional reporting.
- Expands youth prevention and recovery grants to include secondary schools and peer-to-peer support ($10–$15 million annually).
- Enhances the CAREER Act for workforce grants in high-overdose areas, adding transportation support and extending the recovery housing pilot through 2030 ($12 million annually).
- Extends programs addressing economic impacts of the opioid crisis through 2030.
Title IV: Miscellaneous Matters
- Allows pharmacies to deliver certain controlled substances (Schedules III–V) to prescribing practitioners for specific treatments like detoxification or under risk mitigation plans.
- Expands required training for prescribers of controlled substances, including for podiatrists and family physicians, effective retroactively to December 2022.
Significant Changes to Existing Law
- Funding Increases and Extensions: Most programs' authorizations shift from 2019–2023 to 2026–2030, with many budgets raised (e.g., overdose prevention from $496 million to $505.579 million; first responder training from $36 million to $57 million).
- Scope Expansions: Broadens focus beyond opioids to include other substances (e.g., heroin, synthetic drugs); adds fentanyl-specific education, cybersecurity for hotlines, FASD as a standalone program, and innovative tools like test strips.
- New Requirements: Introduces reporting on cybersecurity incidents, evaluations of regional centers, public input on opioid assessments, and a fentanyl work group with annual reports to Congress.
- Flexibility and Simplifications: Removes vendor mandates for PDMPs, eliminates grant subsections for treatment access, and allows transportation funding under CAREER Act (up to 5%).
- Technical Updates: Capitalizes "Tribe" and "Tribal" for consistency; redesignates sections; extends sunsets (e.g., coordinating committee to 2030).
Potential Impacts
- Government Agencies: Increases responsibilities and funding for the Department of Health and Human Services (HHS), FDA, DEA, and CDC, including new reporting, guidance, and interagency coordination. May strain budgets but enhance oversight of public health crises. No direct international relations impacts noted.
- Citizens: Improves access to prevention education, treatment, recovery support, and overdose reversal tools, potentially reducing deaths and supporting families affected by SUD or FASD. Benefits high-risk groups like pregnant women, youth, and rural communities through targeted grants.
- Broader Effects: Could lower healthcare costs long-term by promoting nonaddictive alternatives and early interventions; supports workforce reentry for those in recovery, aiding economic recovery in affected areas.
Main Stakeholders Affected
- Individuals and Families: People with SUD, pregnant/postpartum women, youth, those with FASD or trauma, and overdose victims/survivors.
- Healthcare Providers: Doctors, nurses, addiction specialists, first responders, and peer support workers, who gain training, loan repayments, and resources.
- Governments and Organizations: States, Indian Tribes/Tribal organizations, local agencies, nonprofits, schools, and recovery centers eligible for grants and technical assistance.
- Communities: High-overdose regions, rural areas, and underserved populations benefiting from awareness campaigns and economic support programs.
Notable Legal, Constitutional, or Political Implications
- Legal: Aligns with existing privacy laws (e.g., HIPAA) for surveillance and reporting; potential DEA scheduling changes could affect drug access without altering core Controlled Substances Act criteria. Retroactive training amendments clarify compliance without new burdens.
- Constitutional: No apparent conflicts; enhances federal support for public health under spending clause authority, respecting state/Tribal sovereignty through flexible grants.
- Political: Bipartisan sponsorship signals consensus on opioid response; emphasizes evidence-based approaches and equity (e.g., Tribal inclusion), but annual reporting and evaluations may invite future congressional oversight or adjustments based on outcomes. Budget increases could face fiscal debates.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (8)
Sen. Sanders, Bernard [I-VT], Sen. Murkowski, Lisa [R-AK], Sen. Baldwin, Tammy [D-WI], Sen. Mullin, Markwayne [R-OK], Sen. Hassan, Margaret Wood [D-NH], Sen. Tuberville, Tommy [R-AL], Sen. Hickenlooper, John W. [D-CO], Sen. Husted, Jon [R-OH]
Recent Actions
- 2025-06-18: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-06-18: Introduced in Senate
Bill Versions
- SUPPORT for Patients and Communities Reauthorization Act of 2025 — issued 2025-06-18 — PDF (51 pages)